# Cardiac Insight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiac-insight

- Industry: Medical Devices & Equipment
- Headquarters: Bellevue, US
- Website: www.cardiacinsightinc.com
- Total disclosed funding: $15M
- Latest round: Series D (Feb 11, 2020)
- Investors on record: 3

## About

Cardiac Insight, Inc. develops advanced diagnostic solutions for cardiovascular health, focusing on innovative handheld and wearable ECG devices designed to enhance patient monitoring and care.Founded in 2010 and headquartered in Bellevue, US, Cardiac Insight, Inc. specializes in cardiac diagnostic solutions. The company was acquired by Dreamtech Co., Ltd. in March 2022 for USD 227.57 mn. The CEO is Brad Harlow, who plays a pivotal role in guiding the company’s operations and strategy.Cardiac Insight, Inc. specializes in advanced cardiac diagnostic solutions, primarily through its flagship products, Cardea SOLO and Cardea 20/20. The Cardea 20/20 is a handheld 12-lead ECG device designed to enhance the reliability of electrocardiograms, particularly for detecting cardiovascular conditions in young athletes. Launched in 2013, this product aims to prevent sudden cardiac issues by providing accurate assessments based on the International Consensus Criteria. In 2017, the company expanded its offerings with the Cardea SOLO, a 7-day wearable ambulatory sensor that facilitates continuous ECG monitoring and software-assisted analysis. Both products cater to healthcare providers, including hospitals and clinics, focusing on pediatric and adolescent patient populations. Cardiac Insight's products are marketed in North America and select international markets, effectively addressing the growing demand for innovative cardiac monitoring solutions.Cardiac Insight generates revenue primarily through the sale of its cardiac diagnostic devices, such as the Cardea SOLO and Cardea 20/20, to healthcare facilities and related providers. The revenue model includes direct sales to hospitals and clinics, as well as partnerships with diagnostic service providers that facilitate analysis and reporting of ECG data. Transactions typically involve the purchase of devices, which may be accompanied by ongoing software support and maintenance services. The company’s approach allows healthcare clients to integrate ECG monitoring seamlessly into their patient care processes, leveraging advanced algorithms for precise data interpretation. Cardiac Insight’s commitment to efficiency and support reinforces its value proposition in the market, aligning with the needs of clinicians and patients alike.Following its acquisition in March 2022, Cardiac Insight, Inc. plans to leverage the funding to enhance product development and expand market reach. The company aims to launch new products that build on its existing technology and enhance patient monitoring capabilities. Specific plans include targeting expansion into international markets in Europe and Asia by 2025. This strategic direction, supported by the recent funding from Dreamtech Co., Ltd., will facilitate the company’s efforts to innovate and increase its footprint in the growing global cardiac monitoring sector.

## Funding rounds

- Series D, Feb 11, 2020, $8M — SeaChange
- Series B, Jul 21, 2014, $7.1M — WRF Capital, Welch Allyn

## Investors

- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series B
- Welch Allyn — Series B
- SeaChange (https://capitalatlas.ai/funds/seachange) — Series D